Novartis ianalumab significantly extends disease control in patients with immune thrombocytopenia with only four once-monthly doses
arcticnovartis
Tue, 12/09/2025 – 13:34
Read more about Novartis ianalumab significantly extends disease control in …
Novartis ianalumab significantly extends disease control in patients with immune thrombocytopenia with only four once-monthly doses
arcticnovartis
Tue, 12/09/2025 – 13:34
Read more about Novartis ianalumab significantly extends disease control in …
1 in 4 metastatic breast cancer patients treated with Novartis Kisqali® remain progression-free beyond 4 years
arcticnovartis
Tue, 12/09/2025 – 13:19
Read more about 1 in 4 metastatic breast cancer patients treated with Novartis Kisqali® remain pr…
1 in 4 metastatic breast cancer patients treated with Novartis Kisqali® remain progression-free beyond 4 years
arcticnovartis
Tue, 12/09/2025 – 13:19
Read more about 1 in 4 metastatic breast cancer patients treated with Novartis Kisqali® remain pr…
1 in 4 metastatic breast cancer patients treated with Novartis Kisqali® remain progression-free beyond 4 years
arcticnovartis
Tue, 12/09/2025 – 13:19
Read more about 1 in 4 metastatic breast cancer patients treated with Novartis Kisqali® remain pr…
Novartis data underscore pioneering scientific innovation in hematology and oncology at ASH and SABCS
arcticnovartis
Tue, 11/25/2025 – 07:19
Read more about Novartis data underscore pioneering scientific innovation in hematology and oncology at AS…
Novartis receives FDA approval for Itvisma®, the only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA)
arcticnovartis
Mon, 11/24/2025 – 23:19
Read more about Novartis receives FDA appr…
Novartis projects +5-6% cc sales CAGR 2025-2030, with long-term growth backed by 30+ potential high-value pipeline assets
arcticnovartis
Thu, 11/20/2025 – 07:04
Read more about Novartis projects +5-6% cc sales CAGR 2025-2030, with long-term growth…
Novartis projects +5-6% cc sales CAGR 2025-2030, with long-term growth backed by 30+ potential high-value pipeline assets
arcticnovartis
Thu, 11/20/2025 – 07:04
Read more about Novartis projects +5-6% cc sales CAGR 2025-2030, with long-term growth…
Novartis announces plans to build flagship manufacturing hub in North Carolina
arcticnovartis
Wed, 11/19/2025 – 18:34
Read more about Novartis announces plans to build flagship manufacturing hub in North Carolina
Expansion repres…
